Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
153 participants
INTERVENTIONAL
2015-05-06
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy
NCT02472366
Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
NCT03739593
The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot
NCT00605423
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
NCT02401945
OcuDyne System in the Treatment of AMD
NCT05091476
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ILUVIEN 0.19 MG
All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
ILUVIEN 0.19 MG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ILUVIEN 0.19 MG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alimera Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Consultants of Arizona
Phoenix, Arizona, United States
Retina Centers, P.C.
Tucson, Arizona, United States
Retina and Macula Institute
Glendale, California, United States
Atlantis Eye Care
Huntington Beach, California, United States
Northern California Retina Vitreous Medical Group, Inc.
Mountain View, California, United States
Orange County Retina Medical Group
Santa Ana, California, United States
Eye Care Center of Northern Colorado
Longmont, Colorado, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
Southeast Retina Center, P.C.
Augusta, Georgia, United States
Retina Consultants of Hawaii
‘Aiea, Hawaii, United States
Chicagoland Eye and Retina Foundation
Chicago, Illinois, United States
The University of Illinois at Chicago
Chicago, Illinois, United States
University Retina and Macula Associates
Oak Forest, Illinois, United States
Illinois Retina Associates, SC
Oak Park, Illinois, United States
Carle Foundation Hospital
Urbana, Illinois, United States
Wolfe Eye Clinic
West Des Moines, Iowa, United States
Sabates Eye Center Research Division
Leawood, Kansas, United States
Paducah Retinal Center
Paducah, Kentucky, United States
Eye Associates of Northeast Louisiana
West Monroe, Louisiana, United States
University of Maryland Eye Associates
Baltimore, Maryland, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Wayne State University
Detroit, Michigan, United States
Lifelong Vision Foundation
Chesterfield, Missouri, United States
Discover Vision Centers
Independence, Missouri, United States
Eyesight Ophthalmic Services, PA
Portsmouth, New Hampshire, United States
New Jersey Retina
New Brunswick, New Jersey, United States
Retina Associates of New Jersey
Teaneck, New Jersey, United States
Joseph R. Podhorzer, MD PLLC
Brooklyn, New York, United States
Ophthalmic Consultants of Long Island
Lynbrook, New York, United States
Macula Care
New York, New York, United States
Island Retina
Shirley, New York, United States
Tulsa Retina Consultants
Tulsa, Oklahoma, United States
Laurel Eye Clinic
Brookville, Pennsylvania, United States
Pennsylvania Retina Specialist, PC
Camp Hill, Pennsylvania, United States
Southeastern Retina Associates, PC
Kingsport, Tennessee, United States
Retina Research Center
Austin, Texas, United States
Valley Retina Institute, PA
McAllen, Texas, United States
Medical Center Ophthalmology Associates
San Antonio, Texas, United States
Hampton Roads Retina Center
Chesapeake, Virginia, United States
Virginia Retina Center
Warrenton, Virginia, United States
Cascade Eye and Skin
University Place, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, Werts E. Two-year interim safety results of the 0.2 microg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021 Mar;105(3):414-419. doi: 10.1136/bjophthalmol-2020-315984. Epub 2020 May 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M-01-15-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.